Madsen v. Women's Health Center, Inc.

Greenbrook TMS Announces Closing of Success TMS Acquisition and US$75 Million Credit Facility With Madryn Asset Management

Retrieved on: 
Thursday, July 14, 2022
Professional Services, Mental Health, Health, Medical Devices, Neurology, Finance, General Health, Major depressive disorder, Acquisition, Primary Dealer Credit Facility, Madsen v. Women's Health Center, Inc., Patient, Phrase, Toronto Stock Exchange, Depression, U.S. Securities and Exchange Commission, Annual report, Form 20-F, Private Securities Litigation Reform Act, Wainwright Securities Inc. v. Wall Street Transcript Corp., Transcranial magnetic stimulation, TMS, TSX, LLC, NASDAQ, Nasdaq, Company, Growth, Health, Line of credit, LIBOR, COO, Partnership, Indian stock exchange, FDA, Success, Credit, EBITDA, Mental health, Financial services, Bank, Security (finance), Pharmaceutical industry

In addition, Greenbrook announces today that it and its subsidiaries have entered into a credit agreement for a US$75 million secured credit facility (the Credit Facility) with Madryn Asset Management, LP (Madryn) and its affiliated entities.

Key Points: 
  • In addition, Greenbrook announces today that it and its subsidiaries have entered into a credit agreement for a US$75 million secured credit facility (the Credit Facility) with Madryn Asset Management, LP (Madryn) and its affiliated entities.
  • Key Acquisition and Credit Facility highlights:
    The Company believes the Acquisition of Success TMS 47 TMS centers in the states of Florida, Pennsylvania, Illinois, New Jersey, Nevada and Wisconsin is highly complementary to Greenbrooks existing management regions.
  • The Credit Facility provides Greenbrook with a US$55 million term loan, which was funded on closing.
  • Madryn Asset Management is a leading alternative asset management firm that invests in innovative healthcare companies specializing in unique and transformative products, technologies, and services.

Greenbrook TMS To Acquire Success TMS

Retrieved on: 
Monday, May 16, 2022
Mental Health, Medical Devices, FDA, Health, Other Health, General Health, Debt, Bill, Company, EBITDA, Asset purchase agreement, Indian stock exchange, Purchasing, NASDAQ, Transcranial magnetic stimulation, Date, Success, COVID-19, Toronto Stock Exchange, TSX, Madsen v. Women's Health Center, Inc., Time, Sales, TMS, Indemnity, VWAP, Growth, Real estate, High-performance plastics, Security (finance), Retail, Insurance, Acquisition

Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH) (Greenbrook or the Company), a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today that it has entered into a purchase agreement (the Purchase Agreement) pursuant to which Greenbrook will acquire Check Five LLC, a Delaware limited liability company (doing business as Success TMS) (Success TMS).

Key Points: 
  • Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH) (Greenbrook or the Company), a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today that it has entered into a purchase agreement (the Purchase Agreement) pursuant to which Greenbrook will acquire Check Five LLC, a Delaware limited liability company (doing business as Success TMS) (Success TMS).
  • Acquisition of Success TMS 45 active TMS centers in the states of Florida, Pennsylvania, Illinois, New Jersey, Nevada and Wisconsin.
  • Success TMSs Chief Executive Officer, Benjamin Klein, is expected to join as Chief Operating Officer of Greenbrook, deepening Greenbrooks managerial expertise, and combining best practices of Greenbrook and Success TMS.
  • Pursuant to the Purchase Agreement, Greenbrook, through its wholly-owned U.S. subsidiary, TMS NeuroHealth Centers Inc., will indirectly acquire all of the issued and outstanding equity interests in Success TMS from its parent company, Success Behavioral Holdings LLC (Success Behavioral).

Financial Advisor Kelly Baker Ferrarese joins UBS in Boca Raton, Florida

Retrieved on: 
Tuesday, October 12, 2021
New, Madsen v. Women's Health Center, Inc., Baird (investment bank), Finance, BOCA, UBS, SIX Swiss Exchange, Time, CFP, Retirement, Education, Asset management, Child, Investment banking, Certification, Environment, Bachelor of Science in Nursing, Asia, Texas A&M University, NYSE, Solution, Organization, Florida State University, Financial adviser, Financial services

BOCA RATON, Fla., Oct. 12, 2021 /PRNewswire/ -- UBS Wealth Management USA announced today that Financial Advisor Kelly Baker Ferrarese, CFP, has joined the firm in Boca Raton, FL.

Key Points: 
  • BOCA RATON, Fla., Oct. 12, 2021 /PRNewswire/ -- UBS Wealth Management USA announced today that Financial Advisor Kelly Baker Ferrarese, CFP, has joined the firm in Boca Raton, FL.
  • Kelly joins UBS after a 24-year career as a Wealth Advisor with Wells Fargo Private Bank.
  • As a Certified Financial Planner (CFP), Kelly works with high-net-worth clients, providing a broad range of wealth management services including investment, retirement, and financial planning.
  • Kelly resides in Boca Raton and enjoys traveling with her daughter, who is a junior at Florida State University.

Greenbrook TMS to Acquire Achieve TMS East and Central and Announces US$10 Million Bought Deal Public Offering

Retrieved on: 
Tuesday, September 21, 2021
General Health, Health, Mental Health, Linda, Acquisition, State, Montgomery Street, Growth, Telephone, SEC, Toronto Stock Exchange, Major depressive disorder, Madsen v. Women's Health Center, Inc., Depression, U.S. Securities and Exchange Commission, TMS, Nasdaq, Transcranial magnetic stimulation, Form, Private Securities Litigation Reform Act, Indian stock exchange, Equity capital markets, Sale, NASDAQ, Attention, FDA, Offering, Company, LLC, SEDAR, Register, Wainwright Securities Inc. v. Wall Street Transcript Corp., Suite, TSX, Patient, South Dakota, Registration statement, Phrase, COVID-19, High-performance plastics, Security (finance), Risk management, Pharmaceutical industry

Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH) (Greenbrook or the Company), a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today that it has entered into a purchase agreement pursuant to which Greenbrook will acquire Achieve TMS East, LLC (Achieve TMS East) and Achieve TMS Central, LLC (Achieve TMS Central, and together with Achieve TMS East, Achieve TMS East/Central).

Key Points: 
  • Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH) (Greenbrook or the Company), a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today that it has entered into a purchase agreement pursuant to which Greenbrook will acquire Achieve TMS East, LLC (Achieve TMS East) and Achieve TMS Central, LLC (Achieve TMS Central, and together with Achieve TMS East, Achieve TMS East/Central).
  • Achieve TMS East was founded in 2016, with a vision of increasing accessibility to TMS therapy in the New England area.
  • Since founding its first TMS center in Northampton, Massachusetts, Achieve TMS East has grown to 14 locations in the States of Massachusetts and Connecticut.
  • In 2019, Achieve TMS Easts management team expanded its operations in the Midwest United States through the establishment of Achieve TMS Central which currently operates 3 TMS centers in the State of Iowa.

Triumvira Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform

Retrieved on: 
Tuesday, September 21, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, News, Cain (band), Clinical trial, Partnership, Therapy, Health, SIX Swiss Exchange, Intention, Madsen v. Women's Health Center, Inc., Cancer, Personalized medicine, Multimedia, Patient, Monroe Dunaway Anderson, CEO, Trial of the century, TAC, TCR, Technology, Uncertainty, CORE, IND, Research, CHF, Technology transfer, Time, C3I, Vaccine, Pharmaceutical industry, Fine chemical, Lonza, Triumvira Immunologics, the C3i Center Inc (C3i), LONZA, TRIUMVIRA IMMUNOLOGICS, THE C3I CENTER INC (C3I)

Lonza and Triumvira Immunologics ("Triumvira") announced that the first patient has been dosed with Triumvira's investigational T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, in development for the treatment of HER2-overexpressing cancers.

Key Points: 
  • Lonza and Triumvira Immunologics ("Triumvira") announced that the first patient has been dosed with Triumvira's investigational T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, in development for the treatment of HER2-overexpressing cancers.
  • Triumvira's TAC01-HER2, which harnesses natural T cell activation, was manufactured on Lonza's proprietary Cocoon Platform at C3i Center Inc in Montral, Canada.
  • The Cocoon Platform is an automated and closed platform for patient-scale cell therapy manufacturing, designed to overcome manufacturing challenges associated with patient-scale personalized medicines.
  • Eytan Abraham, Vice President Personalized Medicine, Lonza, commented: "Treating the first HER2-overexpressing cancer patient at MD Anderson with Triumvira's therapy demonstrates the potential of the Cocoon Platform to manufacture therapies at third party manufacturing sites using a decentralized model.

Cybin Inc. Announces 2021 First Quarter Financial Results and Business Highlights

Retrieved on: 
Saturday, August 14, 2021
Biotechnology, General Health, Health, Method, Time, EDGAR, Health Canada, Lists of diseases, Shuping Yang commencement speech controversy, NASDAQ, Net, U.S. Securities and Exchange Commission, Forward-looking statement, Tryptamine, Elgin Mental Health Center, CEO, SEDAR, News, NYSE, Company, TSX, Patent, Food, Disease, NYSE American, Psychiatry, COVID-19, Therapy, Ergoline, Mission statement, NEO, Research, Nature, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Growth, Attention, Psilocybin, Madsen v. Women's Health Center, Inc., Risk, Inc., Depression, International Financial Reporting Standards, Safety, Phenethylamine, International, TMS, Cryptocurrency, Holding company, Pharmaceutical industry

Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, announces the unaudited financial results for the three-month period ended June 30, 2021.

Key Points: 
  • Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, announces the unaudited financial results for the three-month period ended June 30, 2021.
  • Doug Drysdale, CEO of Cybin stated, During the past several months, Cybin has garnered a great deal of attention as an emerging leader in the psychedelic therapeutics space.
  • Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials.
  • If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybins performance and operations.